M Pharmaceutical Appoints Matthew B. Lehman as CEO

M Pharmaceutical Inc. (CSE:MQ) announced today the appointment of Matthew B. Lehman to the position of CEO, effective September 1, 2015. Mr. Lehman brings over 15 years of executive level experience in the development of therapeutics to his new role. Mr. Lehman will be based in the Cincinnati, Ohio area, where the M Pharmaceutical expects to establish its U.S. operating presence and focus on the Company’s most important global market.
Dr. Martin Mintchev, the lead inventor of the Company’s technologies and Company co-founder, will transition from his position as CEO to serve as Chief Scientific Officer.
Mr. Lehman is quoted as saying:

I am pleased to join M Pharmaceutical at this crucial time as we plan for the clinical development and global commercialization of our products, Dr. Mintchev and his team have set a great foundation with innovative technologies and strong patent protection. I look forward to working with Dr. Mintchev to expedite development of the Trimeo Weight Loss Capsules, Trimtec Gastric Neurotimulation System, and eMosquito Wearable Blood Monitor.

Board Director George Tsafalas is quoted as saying:

Mr. Lehman brings the Company the needed skills and experience to carry our innovative biomedical technologies to the world-wide marketplace and lead the Company’s development, I would like to thank Dr. Mintchev for his service as the Company’s founding CEO during our start-up stage and I am pleased that he will continue to serve as the Company’s Chief Scientific Officer.

Click here for the M Pharmaceutical Inc. (CSE:MQ) press release.
Click here for the M Pharmaceutical Inc. (CSE:MQ) profile.